Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and Dyskinesia
Robert A Hauser, Shyamal H Mehta, Daniel Kremens, Dustin Chernick, Andrea E Formella, Robert A Hauser, Shyamal H Mehta, Daniel Kremens, Dustin Chernick, Andrea E Formella
Abstract
Introduction: Gocovri, a bedtime-administered delayed-release/extended-release capsule formulation of amantadine, is the only drug approved by the US Food and Drug Administration as levodopa-adjunctive therapy for the treatment of OFF episodes and/or dyskinesia in Parkinson's disease (PD). Part II of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) assesses patient-perceived disability on experiences of daily living affected by PD motor symptoms. We analyzed Gocovri-related changes in MDS-UPDRS Part II ratings in two placebo-controlled clinical trials.
Methods: Baseline to week 12 changes in MDS-UPDRS Part II total and item scores were compared for Gocovri and placebo using pooled data from phase 3 trials (EASE LID and EASE LID 3).
Results: Baseline mean MDS-UPDRS Part II total score was 15.1 for Gocovri (n = 100) and 15.3 for placebo (n = 96) groups. At week 12, the least squares mean change from baseline was -3.4 for the Gocovri group and -1.4 for placebo (treatment difference, -2.0; 95% CI -3.3 to -0.7; P = 0.004). For Gocovri, change from baseline exceeded a published minimal clinically important difference threshold of 3.05. Gocovri-related treatment differences over placebo were driven primarily by improvement in the scale items of freezing (-0.4; P < 0.0001), tremor (-0.4; P = 0.002), getting out of bed/car/deep chair (-0.3; P = 0.002), and eating tasks (-0.2; P = 0.016).
Conclusion: In addition to improvement in dyskinesia, Gocovri-treated participants experienced improvement in motor aspects of experiences of daily living. Analyses suggest that Gocovri may specifically improve freezing, tremor, getting out of bed/car/deep chair, and eating tasks.
Trial registration: ClinicalTrials.gov identifiers: NCT02136914, NCT02274766.
Keywords: Amantadine extended release; Experiences of daily living; Gocovri; MDS-UPDRS; Motor complications; Parkinson’s disease; Treatment.
© 2021. The Author(s).
Figures
References
- Hauser RA, Pahwa R, Wargin WA, Souza-Prien CJ, McClure N, Johnson R, et al. Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet. 2019;58(1):77–88. doi: 10.1007/s40262-018-0663-4.
- Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol. 2017;74(8):941–949. doi: 10.1001/jamaneurol.2017.0943.
- Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3) Mov Disord. 2017;32(12):1701–1709. doi: 10.1002/mds.27131.
- Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008;23(16):2398–2403. doi: 10.1002/mds.22341.
- Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden C, Calne D, Goldstein M, editors. Recent developments in Parkinson’s disease, vol 2. Florham Park: Macmillan Health Care Information; 1987. p. 153–63, 293–304.
- Rodriguez-Blazquez C, Alvarez M, Arakaki T, Campos Arillo V, Chana P, Fernandez W, et al. Self-assessment of disability in Parkinson's disease: the MDS-UPDRS part II versus clinician-based ratings. Mov Disord Clin Pract. 2017;4(4):529–535. doi: 10.1002/mdc3.12462.
- Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170. doi: 10.1002/mds.22340.
- Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2):75–81. doi: 10.1097/00002826-200003000-00003.
- Movement Disorder Society-Unified Parkinson’s Disease Rating Scale. Milwaukee: Movement Disorder Society; 2019. .
- Horvath K, Aschermann Z, Kovacs M, Makkos A, Harmat M, Janszky J, et al. Minimal clinically important differences for the experiences of daily living parts of Movement Disorder Society-sponsored unified Parkinson's disease rating scale. Mov Disord. 2017;32(5):789–793. doi: 10.1002/mds.26960.
- Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, et al. Author correction to: Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson's disease. CNS Drugs. 2018;32(4):399–400. doi: 10.1007/s40263-018-0510-z.
- Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, et al. Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson's disease. CNS Drugs. 2018;32(4):387–398. doi: 10.1007/s40263-018-0498-4.
- Mehta SH, Pahwa R, Tanner CM, Hauser RA, Johnson R. Effects of Gocovri (amantadine) extended release capsules on non-motor symptoms in patients with Parkinson’s disease and dyskinesia. Neurology and Therapy. 2021 doi: 10.1007/s40120-021-00246-3.
- Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, et al. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord. 2013;19(10):889–893. doi: 10.1016/j.parkreldis.2013.05.017.
- Pahwa R, Isaacson S, Jimenez-Shaheed J, Malaty IA, Deik A, Johnson R, et al. Impact of dyskinesia on activities of daily living in Parkinson's disease: results from pooled phase 3 ADS-5102 clinical trials. Parkinsonism Relat Disord. 2019;60:118–125. doi: 10.1016/j.parkreldis.2018.09.005.
- Okuma Y. Practical approach to freezing of gait in Parkinson's disease. Pract Neurol. 2014;14(4):222–230. doi: 10.1136/practneurol-2013-000743.
- Cucca A, Biagioni MC, Fleisher JE, Agarwal S, Son A, Kumar P, et al. Freezing of gait in Parkinson's disease: from pathophysiology to emerging therapies. Neurodegener Dis Manag. 2016;6(5):431–446. doi: 10.2217/nmt-2016-0018.
- Heremans E, Nieuwboer A, Vercruysse S. Freezing of gait in Parkinson's disease: where are we now? Curr Neurol Neurosci Rep. 2013;13(6):350. doi: 10.1007/s11910-013-0350-7.
- Giladi N. Medical treatment of freezing of gait. Mov Disord. 2008;23(suppl 2):S482–S488. doi: 10.1002/mds.21914.
- Malkani R, Zadikoff C, Melen O, Videnovic A, Borushko E, Simuni T. Amantadine for freezing of gait in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(6):266–268. doi: 10.1097/WNF.0b013e31826e3406.
- Diederich NJ, Fenelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009;5(6):331–342. doi: 10.1038/nrneurol.2009.62.
- Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996–1001. doi: 10.1001/archneurol.2010.166.
- Lee AH, Weintraub D. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012;27(7):858–863. doi: 10.1002/mds.25003.
- Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 2 Study): interim results of an open-label safety study. J Parkinsons Dis. 2017;7(3):511–522. doi: 10.3233/JPD-171134.
- Turcano P, Mielke MM, Bower JH, Parisi JE, Cutsforth-Gregory JK, Ahlskog JE, et al. Levodopa-induced dyskinesia in Parkinson disease: a population-based cohort study. Neurology. 2018;91(24):e2238–e2243. doi: 10.1212/WNL.0000000000006643.
- Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, et al. Parkinson's patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102. Mov Disord Clin Pract. 2018;5(2):183–190. doi: 10.1002/mdc3.12595.
Source: PubMed